Front Pharmacol. 2023; 8(14):1237234 doi 10.3389/fphar.2023.1237234
This meta-analysis by Wei, et al. found that JAKi therapy was not associated with a higher risk of MACE than treatment with adalimumab, abatacept, or placebo. However, a higher incidence of all-cause mortality was observed with tofacitinib treatment than with adalimumab treatment.
Analysis included 14 RCTs with a total sample size of 13,524 participants. A frequentist approach with random-effects models was used to investigate MACE and all-cause mortality. Comparative data were given a GRADE rating, with variables ranging from moderate to very low.